-
Mashup Score: 1
In 1994, the innovative minds of a research group at the University of Munich, led by Amgen vice president Dr. Peter Kufer, made a monumental discovery. Aiming to use the human immune system to fight cancer cells, Dr. Kufer’s team invented Bispecific T-cell Engager (BiTE®) technology.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4New Apprentice Program Draws Talent from Unexpected Sources - 1 day(s) ago
With talent as a top strategic priority for Amgen, this program fits squarely into Amgen’s focus on developing a future-ready workforce with employees who represent a diversity of backgrounds and experiences.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8Amgen's Nobel Laureate Network: A Catalyst for Innovation - 4 day(s) ago
The exceptional caliber of scientists at Amgen is evident not only in the groundbreaking research they conduct, but also in where they train. A number of the company’s researchers come from the labs of prestigious scientists, including Nobel laureates, bringing a wealth of knowledge and pioneering experience with them.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
In 1994, the innovative minds of a research group at the University of Munich, led by Amgen vice president Dr. Peter Kufer, made a monumental discovery. Aiming to use the human immune system to fight cancer cells, Dr. Kufer’s team invented Bispecific T-cell Engager (BiTE®) technology.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8Amgen's Nobel Laureate Network: A Catalyst for Innovation - 10 day(s) ago
The exceptional caliber of scientists at Amgen is evident not only in the groundbreaking research they conduct, but also in where they train. A number of the company’s researchers come from the labs of prestigious scientists, including Nobel laureates, bringing a wealth of knowledge and pioneering experience with them.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8New Apprentice Program Draws Talent from Unexpected Sources - 11 day(s) ago
With talent as a top strategic priority for Amgen, this program fits squarely into Amgen’s focus on developing a future-ready workforce with employees who represent a diversity of backgrounds and experiences.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
In 1994, the innovative minds of a research group at the University of Munich, led by Amgen vice president Dr. Peter Kufer, made a monumental discovery. Aiming to use the human immune system to fight cancer cells, Dr. Kufer’s team invented Bispecific T-cell Engager (BiTE®) technology.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3New Apprentice Program Draws Talent from Unexpected Sources - 18 day(s) ago
With talent as a top strategic priority for Amgen, this program fits squarely into Amgen’s focus on developing a future-ready workforce with employees who represent a diversity of backgrounds and experiences.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1A Fight for Hope: Inspiring Others Through Childhood B-ALL - 19 day(s) ago
In the middle of an icy Texas night, Chaundra Dixon raced through treacherous roads with her young son, MJ, in the backseat. His pain grew steadily, with his condition worsening progressively until it eventually reached a critical point. Despite numerous hospital visits, doctors attributed his symptoms to growing pains or even COVID-19.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5New Apprentice Program Draws Talent from Unexpected Sources - 22 day(s) ago
With talent as a top strategic priority for Amgen, this program fits squarely into Amgen’s focus on developing a future-ready workforce with employees who represent a diversity of backgrounds and experiences.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
🧬BiTE® cancer innovation: B-ALL & beyond 🧬 Discover how @Amgen aims to maximize the therapeutic potential of our BiTE® technology to tackle cancer frontiers. 🔗 https://t.co/pgsZZJf0fN https://t.co/15DEVdQ64B